Cellebrite DI shares dropped more than 30% to a new 52-week low after the company reported second-quarter adjusted earnings of 11 cents per share, matching analyst expectations, while revenue of $131.14 million missed the $131.87 million consensus estimate despite rising 15.8% from a year earlier. The company said revenue and annual recurring revenue growth came in below expectations, guided third-quarter sales to $145 million to $148 million versus a $150.3 million market forecast, cut full-year 2026 revenue guidance to $555 million to $561 million from $565 million to $571 million, and lowered full-year ARR guidance to $550 million to $560 million from $567 million to $573 million. Newly appointed CEO Shiv Ramji said the shortfall reflected timing delays on large transactions with U.S. federal and European government customers facing new procurement requirements, and said management is tightening sales execution and forecasting discipline.